ALMS announced a $175M public offering following positive Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis; Morgan Stanley raised its price target to $33 from $22 and boosted probability of success to 80%, citing competitive efficacy, as the company seeks to capitalize on momentum and fund continued development$Alumis(ALMS)$ 增发